Serum ADMA, endothelial dysfunction, and atherosclerosis in hypervolemic hemodialysis patients
Serum ADMA, endothelial dysfunction, and atherosclerosis in hypervolemic hemodialysis patients
Background/aim: Asymmetric dimethyl arginine (ADMA) is a strong predictor of cardiovascular disease and mortality in patientsunder hemodialysis treatment. We aimed to investigate the relationship among volume status, endothelial dysfunction, and ADMA inhemodialysis patients.Materials and methods: A total of 120 patients with a history of hemodialysis treatment were included. ADMA and CRP weremeasured. Echocardiographic evaluation and carotid artery intima–media thickness (CIMT) measurements were performed. Patientswere divided into two groups according to clinical evaluation, ultrafiltration rate, vena cava inferior diameter (VCI), and cardiothoracicindex (CTI); the two groups were hypervolemic and normovolemic.Results: The hypervolemic group included 61 patients while the normovolemic group included 59 patients. CIMT was higher in thehypervolemic group, but this result was not statistically significant (0.95 mm versus 0.85 mm, P = 0.232). There was a statisticallysignificant difference between the hypervolemic and normovolemic groups in terms of ADMA (P < 0.001) (0.69 ± 0.57 µmol/L and 0.41± 0.04 µmol/L, respectively). Positive correlations were observed between serum ADMA, VCI, CTI, CRP, CIMT, and cardiac mass (P< 0.001, P = 0.016, P < 0.001, P = 0.006, P = 0.022, respectively), and negative correlations were observed between ADMA and ejectionfraction and albumin (P = 0.024, P = 0.024, respectively). In multiple linear regression analysis, ADMA was independently associatedwith age, systolic blood pressure, CTI, and volume status.Conclusion: ADMA may be a potential determinant of hypervolemia as well as atherosclerosis in patients under hemodialysis treatment.
___
- Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van WD,
Bunnapradist S, Horwich TB, Fonarow GC. Fluid retention is
associated with cardiovascular mortality in patients undergoing
long-term hemodialysis. Circulation 2009; 119: 671-679.
- Muntner, JH, Astor BC, Folsom AR, Coresh J. Traditional and
nontraditional risk factors predict coronary heart disease in
chronic kidney disease: results from the Atherosclerosis Risk
in Communities study. J Am Soc Nephrol 2005; 16: 529-538.
- Agarwal R. Hypervolemia is associated with increased
mortality among hemodialysis patients. Hypertension 2010;
56: 512-517.
- Foley RN, Herzog CA, Collins AJ. Blood pressure and longterm mortality in United States hemodialysis patients: USRDS
Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-1790.
- Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ,
Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C,
Bommer J et al. Longer treatment time and slower ultrafiltration
in hemodialysis: associations with reduced mortality in the
DOPPS. Kidney Int 2006; 69: 1222–1228.
- Tetsuka T, Ando Y, Ono S, Asano Y. Change in inferior vena
caval diameter detected by ultrasonography during and after
hemodialysis. ASAIO J 1995; 41: 105-110.
- Yashiro M, Kamata T, Yamadori N, Tomita M, Muso E. Evaluation
of markers to estimate volume status in hemodialysis patients:
atrial natriuretic peptide, inferior vena cava diameter, blood
volume changes and filtration coefficients of microvasculature.
Ther Apher Dial 2007; 11: 131-137.
- Lieb W, Benndorf RA, Benjamin EJ, Sullivan LM, Maas R,
Xanthakis V, Schwedhelm E, Aragam J, Schulze F, Böger RH
et al. Plasma asymmetric dimethylarginine, L-arginine, and
left ventricular structure and function in a community-based
sample. Atherosclerosis 2009; 204: 282-287.
- Shafi T, Hostetter TH, Meyer TW, Hwang S, Hai X, Melamed
ML, Banerjee T, Coresh J, Powe NR. Serum asymmetric and
symmetric dimethylarginine and morbidity and mortality in
hemodialysis patients. Am J Kidney Dis 2017; 70: 48-58.
- Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations
regarding quantitation in M-mode echocardiography: results of
a survey of echocardiographic measurements. Circulation 1978;
58: 1072-1083.
- Shin SJ, Kim HW, Chung S, Chung HW, Lee SJ, Kim YS, Bang
BK, Chang YS, Park CW. Late referral to a nephrologist increases
the risk of uremia related cardiac hypertrophy in patients on
hemodialysis. Nephron Clin Pract 2007; 107: 139-146.
- Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular
mass in chronic kidney disease and ESRD. Clin J Am Soc
Nephrol 2009; 4: 79-91.
- Agarwal R. Interdialytic hypertension: an update. Adv Chronic
Kidney Dis 2011; 18: 11-16.
- London GM, Marchais SJ, Guerin AP, Metivier F, Pannier B.
Cardiac hypertrophy and arterial alteration in end-stage renal
disease. Hemodynamic factors. Kidney Int 1993; 43: 42-49.
- Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G,
Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J et al.
Plasma concentration of asymmetrical dimethylarginine and
mortality in patients with end-stage renal disease: a prospective
study. Lancet 2001; 358: 2113-2117.
- Ozkahya M, Ok E, Cirit M, Aydin S, Akcicek F, Basci A,
Dorhout Mees EJ. Regression of left ventricular hypertrophy in
hemodialysis patients by ultrafiltration and reduced salt intake
without antihypertensive drugs. Nephrol Dial Transplant 1998;
13: 1489-1493.
- de Castro Júnior JR, Fernandes N, Lacet TB, Maia FS, Bonato
GR, Nogueira C, Barberato SH, de Paula RB. Total body water
reduction in subjects with chronic kidney disease on peritoneal
dialysis is associated with a better hypertension control. J Bras
Nefrol 2014; 36:482-489.
- Ozturk S, Karadag S, Yegen M, Gursu M, Uzun S, Aydin
Z, Gurdal A, Koldas M, Kumbasar B, Kazancioglu R. The
relationship of plasma ADMA levels with cardiac functions
and metabolic parameters in peritoneal dialysis patients. Clin
Exp Nephrol 2013; 17: 431-436.
- Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger
O, Massy Z. Emerging biomarkers for evaluating cardiovascular
risk in the chronic kidney disease patient: how do new pieces
fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-
5221.
- Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A,
Hino A, Hirai Y, Imaizumi T. Plasma levels of asymmetric
dimethylarginine (ADMA) are related to intima–media
thickness of the carotid artery: an epidemiological study.
Atherosclerosis 2007; 191: 206-210.
- Zoccali C, Benedetto FA, Renkemaas, Mallamaci F, Tripepi
G, Malatino LS, Böger R; CREED Investigators. Asymmetric
dimethylarginine, C-reactive protein, and carotid intima–
media thickness in end-stage renal disease. J Am Soc Nephrol
2002; 13: 490-496.
- Zoccali C, Mallamaci F, Maas R. Left ventricular hypertrophy
cardiac remodeling and asymmetric dimethylarginine
(ADMA) in hemodialysis patients. Kidney Int 2002; 62: 339-
345.
- London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME,
Day M, Metivier F. Cardiac and arterial interactions in endstage renal disease. Kidney Int 1996; 50: 600-608.
- Avci E, Coskun S, Cakir E, Kurt Y, Ozgur Akgul E, Bilgi
C. Relations between concentrations of asymmetric
dimethylarginine and neopterin as potential risk factors for
cardiovascular diseases in haemodialysis-treated patients. Ren
Fail 2008; 30: 784-790.
- Allawi AAD. Malnutrition, inflammation, and atherosclerosis
(MIA syndrome) in patients with end-stage renal disease
on maintenance hemodialysis (a single centre experience).
Diabetes Metab Syndr 2017; 17: 302-308.
- Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M,
Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated
atherosclerosis, aortic aneurysm formation, and ischemic heart
disease in apolipoprotein E/endothelial nitric oxide synthase
double-knock-out mice. Circulation 2001; 104:448-454.
- Hattler BG, Oddis CV, Zeevi A, Luss H, Shah N, Geller DA,
Billiar TR, Simmons RL, Finkel MS. Regulation of constitutive
nitric oxide synthase activity by the human heart. Am J Cardiol
1995; 76: 957-959.